natgillin/translations-raw huggingface dataset:
Reproduction toxicity studies showed reduced gamete maturation in rat and adverse effects on fertilization. 
Ispitivanja reproduktivne toksičnosti pokazala su smanjeno sazrijevanje gameta u štakora kao i štetne učinke na oplodnju.
If you accidentally take several tablets too many, contact your doctor or pharmacist. 
Ako slučajno uzmete nekoliko tableta previše, obratite se svom liječniku ili ljekarniku.
These changes in the pharmacokinetics of telithromycin do not necessitate dosage adjustment as telithromycin exposure remains within a well tolerated range. 
Ove promjene u farmakokinetici telitromicina ne zahtijevaju prilagodbu doze jer izloženost telitromicinu ostaje u granicama dobre podnošljivosti.
In subjects over 65 (median 75 years), the maximum plasma concentration and AUC of telithromycin were increased approximately 2-fold compared with those achieved in young healthy adults. 
U ispitanika starijih od 65 godina (medijan 75 godina), maksimalna koncentracija u plazmi i AUC telitromicina bili su približno dvostruko veći u odnosu na vrijednosti u mladih zdravih odraslih osoba.
Hypersensitivity to the active substance, to any of the macrolide antibacterial agents, or to any of the 
Preosjetljivost na djelatnu tvar, na bilo koji makrolidni antibiotik ili na bilo koju od pomoćnih tvari
When metoprolol (a CYP2D6 substrate) was coadministered with Ketek, metropolol Cmax and AUC were increased by approximately 38%, however, there was no effect on the elimination half-life of metoprolol. 
Kada se metoprolol (supstrat CYP2D6) primjenjivao istodobno s lijekom Ketek, Cmax i AUC metropolola povećali su se za oko 38%, no nije bilo učinka na poluvrijeme eliminacije metoprolola.
Telithromycin is excreted in the milk of lactating animals, at concentrations about 5 times those of maternal plasma. 
Telitromicin se izlučuje u mlijeko životinja u laktaciji, u koncentracijama oko 5 puta većima od onih u plazmi majke.
L. pneumophila is highly susceptible to telithromycin in vitro, however, the clinical experience of the treatment of pneumonia caused by legionella is limited. 
L. pneumophila je vrlo osjetljiva na telitromicin in vitro, no kliničko iskustvo u liječenju pneumonija uzrokovanih legionelom je ograničeno.
• terfenadine or astemizole (allergic problems) 
• terfenadin ili astemizol (za alergijske tegobe)
Telithromycin inhibits protein synthesis by interacting with domains II and V of the 23S ribosomal RNA of the 50S ribosome subunit. 
Telitromicin inhibira sintezu proteina interakcijom s domenama II i V na 23S RNK-komponenti ribosomske podjedinice 50S.
S.C. Zentiva S.A. B-dul Theodor Pallady nr. 50, sector 3, Bucureşti, cod 032266, Romania 
S.C. Zentiva S.A. B-dul Theodor Pallady nr. 50, sector 3, Bukurešt, cod 032266, Rumunjska
Very common side effects (may affect more than 1 in 10 people) - diarrhoea, usually mild and temporary. 
Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) - proljev, obično blag i prolazan.
The main circulating compound in plasma is telithromycin. 
Glavni cirkulirajući spoj u plazmi je telitromicin.
If you are breast-feeding do not take Ketek. 
Ako dojite, nemojte uzimati Ketek.
The mean maximum white blood cell concentration of telithromycin was 83±25 mg/l. 
Prosječna maksimalna koncentracija telitromicina u bijelim krvnim stanicama bila je 83 ± 25 mg/l.
Experience of treatment of infections caused by penicillin/or erythromycin resistant S. pneumoniae is limited, but so far, clinical efficacy and eradication rates have been similar compared with the treatment of susceptible S. pneumoniae. 
Iskustvo u liječenju infekcija uzrokovanih S. pneumoniae rezistentnim na penicilin ili eritromicin je ograničeno, ali su do sada klinička djelotvornost i stope eradikacije bile slične u usporedbi s rezultatima liječenja osjetljivog S. pneumoniae.
The recommended dose is 800 mg once a day i.e. two 400 mg tablets once a day. 
Preporučena doza je 800 mg jedanput na dan, tj. dvije tablete od 400 mg jedanput na dan.
If you notice any of the following, stop taking Ketek and tell your doctor immediately: - Allergic or skin reactions such as face swelling, general allergic reactions including allergic shock, or serious skin conditions associated with red spots, blisters (frequency not known). 
Ako primijetite bilo što od navedenog, prestanite uzimati Ketek i odmah obavijestite svog liječnika: - alergijske ili kožne reakcije poput oticanja lica, opće alergijske reakcije uključujući alergijski šok ili ozbiljne promjene na koži praćene crvenim mrljama i mjehurićima (učestalost nije
In case the combination is considered necessary, the dose of the calcium channel blocker should be reduced and close clinical monitoring of efficacy and safety in the patient should be exercised. 
Ako se takva kombinacija smatra neophodnom, potrebno je smanjiti dozu blokatora kalcijevih kanala te pažljivo klinički pratiti djelotvornost i sigurnost primjene lijeka u bolesnika.
Although Ketek has no clinically relevant pharmacokinetic or pharmacodynamic interaction with warfarin after single dose administration, more frequent monitoring of prothrombin time/INR (International Normalised Ratio) values should be considered during concomitant treatment. 
Iako nema klinički značajne farmakokinetičke ni farmakodinamičke interakcije između lijeka Ketek i varfarina nakon primjene jedne doze, treba razmotriti češće kontrole vrijednosti protrombinskog vremena/INR-a (međunarodnog normaliziranog omjera) tijekom njihove istodobne primjene.
QT interval prolongation 
Produljenje QT-intervala
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 9 July 2001 
Datum prvog odobrenja: 9. srpnja 2001.
The recommended dose of Ketek for adults and children of 12 years and older is two tablets of 400 mg once daily (800 mg once daily). 
Preporučena doza lijeka Ketek za odrasle i djecu u dobi od 12 ili više godina su dvije tablete od 400 mg jedanput na dan (800 mg jedanput na dan).
The usual duration of treatment is 5 days for infections of the throat, infections of the sinuses, chest infections in patients with long standing breathing difficulties and 7 to 10 days for pneumonia. 
Liječenje obično traje 5 dana kod infekcija grla, infekcija sinusa i infekcija dišnog sustava u bolesnika koji imaju dugotrajne poteškoće s disanjem, a 7 do 10 dana u slučaju upale pluća.
The increase exposure to metoprolol may be of clinical importance in patients with heart failure treated with metoprolol. 
Povećana izloženost metoprololu može biti od kliničkog značaja u bolesnika sa zatajenjem srca koji se liječe metoprololom.
No dosage adjustment is necessary in patients with mild, moderate, or severe hepatic impairment, however the experience in patients with impaired hepatic function is limited. 
Nije potrebno prilagođavati dozu u bolesnika s blagim, umjerenim ili teškim oštećenjem jetre, no iskustvo u bolesnika s oštećenjem funkcije jetre je ograničeno.
Telithromycin is an inhibitor of CYP3A4 and CYP2D6, but has no or limited effect on CYP1A, 2A6, 2B6, 2C8, 2C9, 
Telitromicin je inhibitor CYP3A4 i CYP2D6, ali nema učinka ili mu je učinak slab prema CYP1A, 2A6, 2B6, 2C8, 2C9, 2C19 i 2E1.
Calcium channel blockers that are metabolized by CYP3A4 
Blokatori kalcijevih kanala koji se metaboliziraju putem CYP3A4
Intravenous dosage of midazolam should be adjusted as necessary and monitoring of the patient should be undertaken. 
Po potrebi treba prilagoditi intravensku dozu midazolama i nadzirati bolesnika.
After oral administration of radiolabelled telithromycin, 76% of the radioactivity was recovered from faeces, and 17% from the urine. 
Nakon peroralne primjene radioaktivno obilježenog telitromicina 76% radioaktivnosti je ustanovljeno u fecesu, a 17% u mokraći.
- hallucination (seeing or hearing things that are not there) 
- halucinacije (kada vidite, osjećate ili čujete stvari koje nisu prisutne) - gubitak osjeta okusa i mirisa
• Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1). 
• tonzilitis/faringitis uzrokovan bakterijom Streptococcus pyogenes, kao alternativa u slučaju kad nije prikladna primjena beta-laktamskih antibiotika u zemljama/područjima sa značajnom prevalencijom S. pyogenes rezistentnog na makrolide, kada je rezistencija posredovana genima ermTR ili mefA (vidjeti dio 4.4 i 5.1).
In similarity to some macrolides, telithromycin caused a prolongation of QTc interval in dogs and on action potential duration in rabbit Purkinje fibers in vitro. 
Slično nekim makrolidima, telitromicin je uzrokovao produljenje QTc-intervala kod pasa kao i produljenje trajanja akcijskog potencijala u Purkinjeovim vlaknima kunića in vitro.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed 
Nositelj odobrenja obavljat će dodatne farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom, a koji je opisan u Modulu 1.8.2
History of congenital or a family history of long QT syndrome (if not excluded by ECG) and in patients with known acquired QT interval prolongation. 
Prirođeni sindrom produljenog QT-intervala u osobnoj ili obiteljskoj anamnezi (ako se ne isključi EKG-om) i bolesnici s poznatim stečenim produljenjem QT-intervala.
Slight reductions in fertility indices were seen in rats at parentally toxic doses higher than 150 mg/kg. 
U štakora je opaženo malo smanjenje indeksa plodnosti pri dozama toksičnima za roditelje višima od 150 mg/kg.
Other metabolites were detected in plasma, urine and faeces and represent less or equal than 3% of plasma 
Ostali metaboliti prisutni su u plazmi, mokraći i fecesu i čine manje od 3% AUC-a u plazmi.
For those benzodiazepines which are not metabolised by CYP3A4 (temazepam, nitrazepam, lorazepam) an interaction with Ketek is unlikely. 
Za benzodiazepine koji se ne metaboliziraju pomoću CYP3A4 (temazepam, nitrazepam, lorazepam) nije vjerojatna interakcija s Ketekom.
Visual disturbances included blurred vision, difficulty focusing, and diplopia. 
Smetnje vida obuhvaćale su zamagljen vid, otežano fokusiranje i diplopiju.
The combination is contraindicated (see section 4.3). 
Ova je kombinacija kontraindicirana (vidjeti dio 4.3).
Ketek may produce a similar interaction with lovastatin and atorvastatin which are also mainly metabolised by CYP3A4. 
Ketek može proizvesti sličnu interakciju s lovastatinom i atorvastatinomom, koji se također uglavnom metaboliziraju putem CYP3A4.
Caution should be taken when S. aureus is the suspected pathogen and there is a likelihood of erythromycin resistance based on local epidemiology. 
Potreban je oprez pri sumnji da je uzročnik S. aureus, a prema lokalnim epidemiološkim podacima postoji vjerojatnost rezistencije na eritromicin.
In these patients, co-administration of Ketek and metoprolol, a CYP2D6 substrate, should be considered with caution. 
U tih bolesnika istodobnu primjenu lijeka Ketek i metoprolola, supstrata CYP2D6, treba razmatrati uz oprez.
• When treating infections caused by known or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1): 
• infekcije uzrokovane sojevima s poznatom ili suspektnom rezistencijom na beta-laktame i/ili makrolide (na temelju anamneze bolesnika ili nacionalnih i/ili regionalnih podataka o rezistenciji) koji su obuhvaćeni antibakterijskim spektrom telitromicina (vidjeti dio 4.4 i 5.1):
In haemodialysed patients, the posology should be adjusted so that Ketek 800 mg is given after the dialysis session (see also section 5.2). 
U bolesnika na hemodijalizi doziranje treba prilagoditi na način da se Ketek u dozi od 800 mg primijeni nakon dijalize (vidjeti također dio 5.2).
Plasma exposures based on free fraction of active substance, at the no observed adverse effect levels ranged from 1.6 to 13 times the expected clinical exposure. 
Izloženost u plazmi, s obzirom na slobodnu frakciju djelatne tvari, pri kojoj nisu zabilježeni štetni učinci bila je od 1,6 do 13 puta veća od očekivane izloženosti u kliničkoj primjeni.
If you have kidney problems (severe renal insufficiency) you should take alternating daily doses of 800 mg (two tablets of 400 mg) and 400 mg (one tablet of 400 mg), starting with the 800 mg dose. 
Ako imate probleme s bubrezima (teško oštećenje funkcije bubrega) trebate naizmjence uzimati dnevnu dozu od 800 mg (dvije tablete od 400 mg) i 400 mg (jednu tabletu od 400 mg), a liječenje počinjete s dozom od 800 mg.
Transient loss of consciousness, paraesthesia 
prolazan gubitak svijesti, parestezija parosmija
- if you have kidney problems (severely impaired renal function) and/or liver problems (severely impaired hepatic function), do not take Ketek while taking other medicines containing any of the following active substances: 
- ako imate probleme s bubrezima (teško oštećenje funkcije bubrega) i/ili probleme s jetrom (teško oštećenje funkcije jetre), nemojte uzimati Ketek dok uzimate druge lijekove koji sadrže neku od sljedećih djelatnih tvari:
Ventricular arrhythmias (including ventricular tachycardia, torsade de pointes) have been reported in patients treated with telithromycin and sometimes occurred within a few hours of the first dose (see 
Ventrikularne artimije (uključujući ventrikularnu tahikardiju, torsades de pointes) prijavljene su u bolesnika liječenih telitromicinom i ponekad su se pojavile unutar nekoliko sati od prve doze (vidjeti
Concomitant treatment with these medicinal products is likely to result in subtherapeutic levels of telithromycin and therefore encompass a risk of treatment failure (see section 4.5). 
Istodobna primjena tih lijekova vjerojatno će rezultirati supterapijskim koncentracijama telitromicina te stoga nosi rizik od neuspjeha liječenja (vidjeti dio 4.5).
Studies in rats and rabbits were inconclusive with respect to potential for teratogenicity; there was equivocal evidence of adverse effects on foetal development at high doses. 
Istraživanja na štakorima i kunićima nisu pružila nedvojben odgovor o mogućoj teratogenosti, a dokazi o štetnim učincima na razvoj fetusa pri visokim dozama
Interaction studies with itraconazole and ketoconazole, two CYP3A4 inhibitors, showed that maximum plasma concentrations of telithromycin were increased respectively by 1.22 and 1.51 fold and AUC by respectively 1.54 fold and 2.0 fold. 
Ispitivanja interakcija s itrakonazolom i ketokonazolom, dvama inhibitorima CYP3A4, pokazala su da su kod istodobne primjene maksimalne koncentracije telitromicina u plazmi porasle 1,22 odnosno 1,51 puta, a njegov AUC 1,54 odnosno 2,0 puta.
The effect of dialysis on the elimination of telithromycin has not been assessed. 
Učinak dijalize na eliminaciju telitromicina još nije ocijenjen.
Ketek is not recommended as first choice in patients with severe renal impairment (creatinine clearance <30 ml/min) or patients with both severe renal impairment and co-existing hepatic impairment, as an optimal dosage format (600 mg) is not available. 
Ketek se ne preporučuje kao prvi izbor u bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) niti u bolesnika koji imaju teško oštećenje bubrega i istodobno oštećenje jetre jer ne postoji prikladan oblik doziranja lijeka (600 mg).
The pharmacokinetics of telithromycin is similar between males and females. 
-Spol Farmakokinetika telitromicina podjednaka je u muškaraca i žena.
Exposure to telithromycin in vitro did select for pneumococcal mutants with increased MICs of telithromycin, generally resulting in MIC values of ≤1 mg/l. 
S izloženošću telitromicinu in vitro izdvojili su se pneumokokni mutanti s povećanim MIK-ovima telitromicina, što je u pravilu rezultiralo vrijednostima MIK-a od ≤ 1 mg/l.
Ketek is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4. 
Ketek je inhibitor CYP3A4 i samo se u posebnim okolnostima smije primjenjivati tijekom liječenja drugim lijekovima koji se metaboliziraju putem CYP3A4.
There were no reports of TdP or other serious ventricular arrhythmias or related syncope in the clinical program and no subgroups at risk were identified. 
U kliničkom programu nisu prijavljeni torsade de pointes niti druge ozbiljne ventrikularne aritmije ili povezani slučajevi sinkope, a nisu utvrđene ni rizične podskupine.
Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen. 
Bolesnicima treba savjetovati da prekinu liječenje i obrate se liječniku ako se razviju znakovi i simptomi jetrene bolesti, kao što su anoreksija, žutica, tamna mokraća, svrbež ili osjetljivost
Hence, telithromycin should be used with caution (see also sections 4.4 and 5.2). 
Stoga telitromicin u tih bolesnika treba primjenjivati uz oprez (vidjeti također dio 4.4 i 5.2).
• ketoconazole or fluconazole (anti-fungal treatment) 
• ketokonazol ili flukonazol (za liječenje gljivičnih infekcija)
If telithromycin treatment is deemed necessary, these patients may be treated with alternating daily doses of 800 mg and 400 mg, starting with the 800 mg 
Ako se liječenje telitromicinom smatra neophodnim, takve se bolesnike može liječiti naizmjeničnim davanjem dnevnih doza od 800 mg i 400 mg, počevši s dozom
>0.5 mg/l 
> 0,5 mg/l > 0,5 mg/l > 8 mg/l > 0,5 mg/l
If pseudomembranous colitis is suspected, the treatment must be stopped immediately and patients should be treated with supportive measures 
Posumnja li se na pseudomembranski kolitis, liječenje se mora odmah prekinuti, a bolesnika liječiti potpornom i/ili specifičnom terapijom.
In in vitro studies the activity of telithromycin was reduced against organisms that express the erythromycin erm(B) or mef(A) related resistance mechanisms. 
U ispitivanjima in vitro aktivnost telitromicina bila je smanjena protiv organizama koji iskazuju mehanizme rezistencije na eritromicin povezane s ekspresijom gena erm(B) ili mef(A).
Furthermore, telithromycin is able to block the formation of the 
Osim toga, telitromicin može blokirati stvaranje ribosomskih podjedinica
The induction gradually decreases during 2 weeks after cessation of treatment with CYP3A4 inducers. 
Indukcija se postupno smanjuje tijekom 2 tjedna nakon prestanka liječenja induktorima CYP3A4.
Ergot alkaloid derivatives (such as ergotamine and dihydroergotamine) By extrapolation from erythromycin A and josamycin, concomitant medication of Ketek and alkaloid derivatives could lead to severe vasoconstriction (“ergotism”) with possibly necrosis of the extremities. 
Derivati ergot alkaloida (poput ergotamina i dihidroergotamina) Sudeći prema iskustvu s eritromicinom A i josamicinom, istodobna primjena lijeka Ketek i derivata alkaloida može dovesti do teške vazokonstrikcije ("ergotizma") s mogućom nekrozom udova.
• saquinavir (anti-HIV treatment) - if you are taking other medicines containing any of the following active substances: 
• sakvinavir (za liječenje HIV infekcije) - ako uzimate druge lijekove koji sadrže neku od sljedećih djelatnih tvari:
Strong CYP3A4 inhibitors must not be co-administered with Ketek in patients with severe renal/or hepatic dysfunction (see section 4.3). 
Snažni inhibitori CYP3A4 ne smiju se primjenjivati zajedno s lijekom Ketek u bolesnika s teškim oštećenjem bubrežne ili jetrene funkcije (vidjeti dio 4.3).
Phospholipidosis (intracellular phospholipid accumulation) affecting a number of organs and tissues (e.g., liver, kidney, lung, thymus, spleen, gall bladder, mesenteric lymph nodes, GI-tract) has been observed in rats and dogs administered telithromycin at repeated doses of 150 mg/kg/day or more for 1 month and 20 mg/kg/day or more for 3-6 months. 
Fosfolipidoza (intracelularna akumulacija fosfolipida) koja zahvaća brojne organe i tkiva (npr. jetru, bubrege, pluća, timus, slezenu, žučni mjehur, mezenterijske limfne čvorove, probavni sustav) zabilježena je u štakora i pasa koji su primali telitromicin u višekratnim dozama od 150 mg/kg na dan ili više tijekom mjesec dana, odnosno 20 mg/kg na dan tijekom 3-6 mjeseci.
In some organisms that are resistant to erythromycin A due to inducible expression of the MLSB resistance determinant, the affinity of telithromycin for the 50S ribosomal subunit is more than 20 
U nekim organizmima koji su rezistentni na eritromicin A zbog inducibilne ekspresije odrednice rezistencije tipa MLSB, afinitet telitromicina za ribosomsku podjedinicu 50S je više od 20 puta veći od afiniteta eritromicina A.
Telithromycin has been shown to decrease the Cmax by 34 % and AUC of sotalol by 20 % due to 
Pokazalo se da telitromicin smanjuje Cmax sotalola za 34% i bioraspoloživost (AUC) za 20% zbog
Telithromycin is an inhibitor of CYP3A4 and a weak inhibitor of CYP2D6. 
Telitromicin je inhibitor CYP3A4 i slab inhibitor CYP2D6.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the 
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava navedenog u Dodatku V.
- The other ingredients are microcrystalline cellulose, povidone (K25), croscarmellose sodium, magnesium stearate in the tablet core as well as talc, macrogol (8000 ), hypromellose (6 cp), titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) in the film-coating. 
- Drugi sastojci su mikrokristalična celuloza, povidon (K25), umrežena karmelozanatrij i magnezijev stearat u jezgri tablete te talk, makrogol (8000), hipromeloza (6cp), titanijev dioksid (E171), žuti željezov oksid (E172) i crveni željezov oksid (E172) u film ovojnici.
When midazolam was coadministered with Ketek, midazolam AUC was increased 2.2-fold after intravenous administration of midazolam and 6.1-fold after oral administration. 
Kad se midazolam davao istodobno s lijekom Ketek, AUC midazolama povećao se 2,2 puta nakon intravenske, a 6,1 puta nakon peroralne primjene midazolama.
Patients with concomitant treatment of pravastatin, rosuvastatin or fluvastatin should be carefully monitored for signs and symptoms of myopathy and rhabdomyolysis. 
Bolesnike koji istodobno uzimaju pravastatin, rosuvastatin ili fluvastatin treba pomno nadzirati zbog mogućih pojava znakova i simptoma miopatije i rabdomiolize.
Ketek 400 mg tablets are light orange, oblong, biconvex, film-coated tablets imprinted with “H3647” on one side and “400” on the other. 
Ketek 400 mg tablete su svijetlonarančaste, ovalne, bikonveksne filmom obložene tablete, s utisnutom oznakom "H3647" na jednoj i "400" na drugoj strani.
During concomitant administration of rifampicin and telithromycin in repeated doses, Cmax and AUC of telithromycin were on average decreased by 79% and 86% respectively. 
Tijekom istodobne primjene rifampicina i telitromicina u ponovljenim dozama, Cmax telitromicina snižen je za prosječno 79%, a AUC za prosječno 86%.
Treatment with these agents should be interrupted during Ketek treatment. 
Primjena ovih lijekova mora se privremeno prekinuti tijekom liječenja lijekom Ketek.
There is no clinically relevant pharmacokinetic interaction of Ketek and theophylline administered as extended release formulation. 
Nema klinički značajne farmakokinetičke interakcije lijeka Ketek i teofilina primijenjenog u obliku s produljenim oslobađanjem.
No carcinogenicity studies have been conducted with telithromycin. 
Nisu provedena ispitivanja kancerogenosti telitromicina.
The rate and extent of absorption is unaffected by food intake, and thus Ketek tablets can be given without regard to food. 
Unos hrane ne utječe na brzinu i opseg apsorpcije pa se Ketek tablete mogu davati neovisno o obroku.
Streptococcus pneumoniae does not demonstrate cross-resistance between erythromycin A and 
Streptococcus pneumoniae ne pokazuje križnu rezistenciju između eritromicina A i telitromicina.
Telithromycin is also a P-glycoprotein inhibitor. 
Telitromicin je i inhibitor P-glikoproteina.